PMID- 32944039
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220416
IS  - 1735-5303 (Print)
IS  - 2345-3656 (Electronic)
IS  - 1735-5303 (Linking)
VI  - 15
IP  - 4
DP  - 2020 Fall
TI  - Investigation of HER-2 Expression an Its Correlation with Clinicopathological 
      Parameters and Overall Survival of Esophageal Squamous Cell Carcinoma Patients.
PG  - 274-281
LID - 10.30699/IJP.2020.113829.2235 [doi]
AB  - BACKGROUND & OBJECTIVE: Human epidermal growth factor receptor 2 (HER-2) exhibits 
      a vast range of expression in esophageal squamous cell carcinoma (ESCC) patients 
      as a biomarker. This paper aimed to investigate HER-2 expression and 
      clinicopathological parameters of esophageal SCC. METHODS: HER-2 expression was 
      assessed in 102 ESCC patients by immunohistochemistry. The HER-2 staining 
      intensity , according to the Gastric HER2 Biomarker1.0.0.1 version of the college 
      of American pathologists (CAP) protocol for gastric and gastroesophageal junction 
      cancers, was graded as 0 (no reactivity in any of the cancer cells' membranes); 
      1+ (pale or hardly noticeable reactivity in the membrane of cancer cells' cluster 
      [>/= 5 neoplastic cells] regardless of the positive cancer cells' percentage); 2+ 
      (weak-to-moderate complete, basolateral, or lateral membranous reactivity 
      regardless of the positive cancer cells' percentage); and 3+ ( strong complete, 
      basolateral, or lateral reactivity in the membrane of the cancer cell cluster 
      regardless of the positive cancer cells' percentage).In this regard, 3+ scored 
      samples were considered as positive. If HER-2 expression was scored 2+, an 
      additional fluorescence in situ hybridization (FISH) was performed. Fisher's 
      exact test was employed for investigating the correlation of HER-2 expression 
      status with patients' clinicopathological characteristics (including age, gender, 
      tumor location, stage, grade, infiltration level, venous invasion, lymphatic 
      invasion, and tumor recurrence). Kaplan-Meier analysis was done for the patients' 
      survival assessments. RESULTS: Five patients (~5%) were HER-2 positive and no 
      significant association was observed between HER-2 expression and 
      clinicopathological properties. In addition, HER-2 expression status exhibited no 
      significant association with the patients' overall survival (P=0.9299). 
      CONCLUSION: HER-2 is not a suitable prognostic biomarker for Iranian ESCC 
      patients.
FAU - Heidarpour, Mitra
AU  - Heidarpour M
AD  - Department of Pathology, Faculty of Medicine, Isfahan University of Medical 
      Sciences, Isfahan, Iran.
FAU - Taheri, Mehran
AU  - Taheri M
AD  - Department of Pathology, Faculty of Medicine, Isfahan University of Medical 
      Sciences, Isfahan, Iran.
FAU - Akhavan, Ali
AU  - Akhavan A
AD  - Department of Radiation Oncology, Faculty of Medicine, Isfahan University of 
      Medical Sciences, Isfahan, Iran.
FAU - Goli, Parvin
AU  - Goli P
AD  - Department of Immunology, Faculty of Medicine, Isfahan University of Medical 
      Sciences, Isfahan, Iran.
FAU - Kefayat, Amirhosein
AU  - Kefayat A
AD  - Department of Oncology, Cancer Prevention Research Center, Faculty of Medicine, 
      Isfahan University of Medical Sciences, Isfahan, Iran.
LA  - eng
PT  - Journal Article
DEP - 20200716
PL  - Iran
TA  - Iran J Pathol
JT  - Iranian journal of pathology
JID - 101515128
PMC - PMC7477677
OTO - NOTNLM
OT  - Esophageal cancer
OT  - Human epidermal growth factor receptor 2
OT  - Squamous cell carcinoma
EDAT- 2020/09/19 06:00
MHDA- 2020/09/19 06:01
PMCR- 2020/09/01
CRDT- 2020/09/18 05:49
PHST- 2020/09/14 00:00 [received]
PHST- 2020/04/22 00:00 [accepted]
PHST- 2020/09/18 05:49 [entrez]
PHST- 2020/09/19 06:00 [pubmed]
PHST- 2020/09/19 06:01 [medline]
PHST- 2020/09/01 00:00 [pmc-release]
AID - 10.30699/IJP.2020.113829.2235 [doi]
PST - ppublish
SO  - Iran J Pathol. 2020 Fall;15(4):274-281. doi: 10.30699/IJP.2020.113829.2235. Epub 
      2020 Jul 16.